HemoShear Revenue and Competitors

Location

$60.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HemoShear's estimated annual revenue is currently $11.2M per year.(i)
  • HemoShear's total funding is $60.1M.

Employee Data

    HemoShear's People

    NameTitleEmail/Phone
    1
    Head DiscoveryReveal Email/Phone
    2
    VP OperationsReveal Email/Phone
    3
    Head Computational BiologyReveal Email/Phone
    4
    VP, CommunicationsReveal Email/Phone
    5
    VP, Legal AffairsReveal Email/Phone
    6
    VP - Organization Development and HRReveal Email/Phone
    7
    Executive Director, Head Discovery BiologyReveal Email/Phone
    8
    Director, Computational BiologyReveal Email/Phone
    9
    Chief Financial OfficerReveal Email/Phone
    10
    Executive Director, Head Exploratory BiologyReveal Email/Phone
    Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
    #1
    $1.4M7-22%N/AN/A
    #2
    $4.3M284%N/AN/A
    #3
    $1.1M70%N/AN/A
    #4
    $3.5M45-52%$56.5MN/A
    #5
    $0.3M20%N/AN/A
    #6
    $4.5M2921%N/AN/A
    #7
    $1.9M129%N/AN/A
    #8
    $7M455%N/AN/A
    #9
    $6.7M435%N/AN/A
    #10
    $2M13-13%N/AN/A
    Add Company

    What Is HemoShear?

    HemoShear LLC is a biotechnology research company that combines its scientific expertise with its proprietary platform technology in research collaborations with pharmaceutical companies to accelerate drug discovery and development. HemoShear has expertise in the areas of human and animal biology, bioinformatics and molecular profiling for target identification and validation, cell-signaling pathway analysis, sophisticated methods to quantify target genes and proteins, assessment of molecular pharmacology, and methods to determine mechanisms of action for drug efficacy and safety. HemoShear's technology platform can be adapted to replicate the biology of human or animal organ systems in both healthy and disease-prone states by applying physiologically accurate hemodynamic forces to primary cell cultures. HemoShear is currently collaborating with several large pharmaceutical companies on programs that span the drug discovery and development spectrum. HemoShear is a privately held company located in Charlottesville, Virginia. To learn more about HemoShear, visit www.hemoshear.com.

    keywords:Biotechnology

    $60.1M

    Total Funding

    N/A

    Number of Employees

    $11.2M

    Revenue (est)

    N/A

    Employee Growth %

    N/A

    Valuation

    N/A

    Accelerator

    HemoShear News

    2021-07-22 - HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

    CHARLOTTESVILLE, Va., July 22, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced that the first two patients have been dosed in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of HST5040, ...

    2021-02-15 - HemoShear Therapeutics Raises $40M in Series A Financing

    HemoShear Therapeutics, Inc., a Charlottesville, Va.-based clinical stage company developing treatments for rare metabolic disorders, has raised $40m in Series A financing. The round was led by Suvretta Capital with participation from Janus Henderson Investors, Adage Capital Management LP and o ...

    2021-02-15 - HemoShear Therapeutics Raises $40M in Series A

    HemoShear Therapeutics, Inc., a Charlottesville, Va.-based clinical stage company developing treatments for rare metabolic disorders, has raised $40m in Series A financing. The round was led by Suvretta Capital with participation from Janus Henderson Investors, Adage Capital Management LP and o ...